RogerJWaltzmanMDMBA

PubMed

• 278 citations
  LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
  Masoud Tavazoie, Ilana Pollack, Raissa Tanqueco, Benjamin N. Ostendorf, Bernardo S. Reis, Foster C. Gonsalves, Isabel Kurth, Celia Andreu-Agullo, Mark L. Derbyshire, J...> ;Cell. 2018 Feb 8
• 1272 citations
  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
  Claire N. Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger J. Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S. Hunter, Richar...> ;The New England Journal of Medicine. 2012 Feb 29
• Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myel...
  Harrison CN, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Cervantes F, Vannucchi AM, Barbui T, Barosi G> ;J. Clin. Oncol.. 2011-06-20
• RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
  Verstovsek S, Kiladjian J, Waltzman RJ, Sandor V, Lukawy J, Garrett WM, Malek K, Huber RM, Vannucchi AM> ;J. Clin. Oncol.. 2011-05-20
• Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibros...
  Harrison CN, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Cervantes F, Vannucchi AM, Barbui T, Barosi G> ;J. Clin. Oncol.. 2011-05-20
• 37 citations
  High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interfe...
  François Guilhot, Brian J. Druker, Richard A. Larson, Insa Gathmann, Charlene So, Roger J. Waltzman, Stephen G. O'Brien> ;Haematologica. 2009 Dec 1
• 27 citations
  Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leu...
  Richard T. Silver, Jorge E. Cortes, Roger J. Waltzman, Manisha Mone, Hagop M. Kantarjian> ;Haematologica. 2009 May 1
• 106 citations
  Invasive Anal Squamous-Cell Carcinoma in the HIV-Positive Patient: Outcome in the Era of Highly Active Antiretroviral Therapy
  Ann Wexler, Anthony M. Berson, Stephen E. Goldstone, Roger J. Waltzman, Jason R. Penzer, Olivier G. Maisonet, Bill McDermott, John Rescigno> ;Diseases of the Colon and Rectum. 2008 Jan 1
• 11 citations
  Communicating about chemotherapy-induced anemia.
  Brad Davidson, Diane Blum, David Cella, Heidi Hamilton, Lillian Nail, Roger Waltzman> ;The Journal of Supportive Oncology. 2007 Jan 1
• 1 citations
  A pilot study to evaluate the safety and clinical outcomes of once-weekly epoetin alfa 80,000 u in anemic patients with cancer receiving chemotherapy.
  Roger J. Waltzman, Denise Williams, Patricia Braly> ;Supportive Cancer Therapy. 2005 Oct 1
• 16 citations
  Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve
  Mei Sheng Duh, Patrick Lefebvre, John Fastenau, Catherine Tak Piech, Roger J. Waltzman> ;The Oncologist. 2005 Jun 1
• Communication regarding chemotherapy-induced anemia and related fatigue: Recommendations from an observational linguistic study.
  Hamilton HE, Blum D, Cella D, Davidson B, Nail L, Waltzman RJ> ;J. Clin. Oncol.. 2005-06-01
• Final hematologic results: Epoetin alfa (EPO) 40,000 U QW vs darbepoetin alfa (DARB) 200 μg Q2W in anemic cancer patients (pts) receiving chemotherapy (CT).
  Waltzman RJ, Croot C, Williams D> ;J. Clin. Oncol.. 2005-06-01
• 65 citations
  Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μg Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy
  Roger J. Waltzman, Christopher Croot, Glen R. Justice, Mark R. Fesen, Veena Charu, Denise Williams> ;The Oncologist. 2005 Sep 1
• 7 citations
  Treatment of chemotherapy-related anemia with erythropoietic agents: current approaches and new paradigms.
  Roger J. Waltzman> ;Seminars in Hematology. 2004 Oct 1
• Treatment of mild anemia.
  Roger J Waltzman> ;Journal of the National Comprehensive Cancer Network. 2004 Sep 1
• Epoetin alfa 40,000 U QW vs darbepoetin alfa 200 mcg Q2W in anemic cancer patients receiving chemotherapy: Preliminary results of a comparative trial.
  Waltzman RJ, Fesen M, Justice GR, Croot C, Williams D> ;J. Clin. Oncol.. 2004-07-15
• Treatment of anemia with epoetin alfa 80,000 U QW in cancer patients receiving chemotherapy.
  Tarabay G, Braly P, Baker JJ, Williams D, Waltzman RJ> ;J. Clin. Oncol.. 2004-07-15
• 8 citations
  Managing hematologic toxicities.
  Gerardo Capo, Roger Waltzman> ;The Journal of Supportive Oncology. 2004 Jan 1
• 11 citations
  Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
  Martee L. Hensley, Dore Lebeau, Larry Leon, Ennapadam Venkatraman, Roger J. Waltzman, Paul Sabbatini, Lois Almadrones, Dennis S. Chi, David R. Spriggs> ;Gynecologic Oncology. 2001 Jun 1
• 88 citations
  Phase II Trial of Paclitaxel in Patients with Soft-Tissue Sarcoma
  Ephraim S. Casper, Roger J. Waltzman, Gary K. Schwartz, Alison Sugarman, David G. Pfister, David H. Ilson, James M. Woodruff, Denis H. Y. Leung, Joseph R. Bertino> ;Cancer Investigation. 1998 Jan 1
• Expand your differential.
  Roger J. Waltzman, Ellin Berman> ;Leukemia Research. 1997 Jan 1
• Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian c...
  Aghajanian, C., Fennelly, D., Shapiro, F., Waltzman, R., Almadrones, L., O'Flaherty, C., O'Conner, K., Venkatraman, E., Barakat, R., Curtin, J., Brown, C., Reich, L., ...> ;J Clin Oncol. 1998 May
• 1 citations
  Primary intravenous paclitaxel and platinum chemotherapy for high-risk Stage I epithelial ovarian carcinoma.
  Dennis S. Chi, Roger J. Waltzman, Richard R. Barakat, D.R. Spriggs> ;European Journal of Gynaecological Oncology. 1999 Jan 1
• Join now to see all

Abstracts/Posters

• A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) ...
  Roger Waltzman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• MT-5111: A novel HER2 targeting engineered toxin body in clinical development. 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020